We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
+1.03%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$746M
AUM Growth
+$13.3M
Cap. Flow
-$7.63M
Cap. Flow %
-1.02%
Top 10 Hldgs %
47.22%
Holding
107
New
21
Increased
25
Reduced
20
Closed
22

Top Buys

Rank Stock Value
1
APGE
Apogee Therapeutics
APGE
+$13.6M
2
MRUS
Merus
MRUS
+$10.9M
3
ARVN icon
Arvinas
ARVN
+$9.84M
4
SYRE icon
Spyre Therapeutics
SYRE
+$9.56M
5
PRQR icon
ProQR Therapeutics
PRQR
+$8.97M

Top Sells

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$13.4M
2
ATXS
Astria Therapeutics
ATXS
+$7.98M
3
VRDN icon
Viridian Therapeutics
VRDN
+$7.94M
4
ONC
BeOne Medicines Ltd
ONC
+$7.86M
5
TERN
Terns Pharmaceuticals
TERN
+$5M

Sector Composition

Rank Sector Weight
1 Healthcare 78.04%
2 Miscellaneous 21.48%
3 Financials 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OMER icon
76
Omeros
OMER
$1.37B
$98.4K 0.01%
+9,958
New +$68.3K
QTTB icon
77
Q32 Bio
QTTB
$357M
$95.6K 0.01%
27,777
– –
IMTXW
78
DELISTED
Immatics N.V. Warrants
IMTXW
$47.1K 0.01%
187,204
– –
SYRS
79
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$34.5K ﹤0.01%
+150,000
New +$180K
SLNO
80
CALL
DELISTED
Soleno Therapeutics
SLNO
$8.99K ﹤0.01%
+200
New +$10.4K
RCKTW
81
DELISTED
Rocket Pharmaceuticals Warrant
RCKTW
$2.57K ﹤0.01%
75,000
– –
ANAB icon
82
PUT
AnaptysBio
ANAB
$1.68B
– –
-200,000
Closed -$6.7M
ATXS
83
DELISTED
Astria Therapeutics
ATXS
– –
-725,106
Closed -$7.98M
BMRN icon
84
BioMarin Pharmaceuticals
BMRN
$12.9B
– –
-15,000
Closed -$1.05M
GNLX icon
85
Genelux
GNLX
$110M
– –
-100,000
Closed -$237K
IMTX icon
86
Immatics
IMTX
$1.46B
– –
-250,000
Closed -$2.85M
IMVT icon
87
CALL
Immunovant
IMVT
$8.11B
– –
-78,000
Closed -$2.22M
KURA icon
88
Kura Oncology
KURA
$1.18B
– –
-687,785
Closed -$13.4M
NVAX icon
89
CALL
Novavax
NVAX
$1.69B
– –
-300,000
Closed -$3.79M
PBYI icon
90
Puma Biotechnology
PBYI
$493M
– –
-250,000
Closed -$638K
PMN icon
91
ProMIS Neurosciences
PMN
$113M
– –
-1,226
Closed -$38.3K
ROIV icon
92
Roivant Sciences
ROIV
$25.2B
– –
-201,587
Closed -$2.33M
SMMT icon
93
CALL
Summit Therapeutics
SMMT
$14B
– –
-140,000
Closed -$3.07M
SPRY icon
94
CALL
ARS Pharmaceuticals
SPRY
$559M
– –
-400,000
Closed -$5.8M
SWTX
95
DELISTED
SpringWorks Therapeutics
SWTX
– –
-147,500
Closed -$4.73M
TERN
96
DELISTED
Terns Pharmaceuticals
TERN
– –
-600,000
Closed -$5M
TEVA icon
97
CALL
Teva Pharmaceuticals
TEVA
$42.4B
– –
-1,000,000
Closed -$18M
VSTM icon
98
Verastem
VSTM
$743M
– –
-400,000
Closed -$1.2M
VYGR icon
99
Voyager Therapeutics
VYGR
$216M
– –
-51,727
Closed -$303K
KYTX icon
100
Kyverna Therapeutics
KYTX
$510M
– –
-119,900
Closed -$586K
1 2 3
4
5

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, Affinity Asset Advisors held 107 positions worth $746M, up 1.8% from $733M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Affinity Asset Advisors's Q4 2024 filing shows 21 new, 25 increased, 20 reduced and 22 closed positions. Its largest new stake was ProQR Therapeutics: 2,825,000 shares worth $7.49M. The largest sale was Kura Oncology, an estimated $13.4M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 82% a quarter earlier, followed by Miscellaneous and Financials.

  • Affinity Asset Advisors's largest Q4 2024 buy was ProQR Therapeutics: 2,825,000 shares worth $7.49M.
  • Affinity Asset Advisors added most to Apogee Therapeutics in Q4 2024, an estimated $13.6M increase.
  • Affinity Asset Advisors's biggest Q4 2024 reduction was Viridian Therapeutics, cutting an estimated $7.94M.
  • Affinity Asset Advisors fully exited Kura Oncology in Q4 2024, selling an estimated $13.4M.
  • Affinity Asset Advisors's ten largest holdings make up 47% of its $746M portfolio in Q4 2024.
  • Affinity Asset Advisors opened 21 new positions and closed 22 in Q4 2024.
  • Affinity Asset Advisors's portfolio value rose 1.8% quarter-over-quarter to $746M.

Based on Affinity Asset Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.